ClinicalTrials.gg
RecruitingNCT03935451EXPANDUpdated Jan 5, 2024

Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease

An Early Phase 1 interventional study of Apixaban 2.5 milligram and Placebo Oral Tablet in IBD, Venous Thromboembolism and Crohn Disease, sponsored by McMaster University. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by McMaster University · Early Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Venous Thromboembolism by McMaster University — 2 open to participants now, 2 under way, 1 of them phase 3. Venous Thromboembolism · McMaster University.

Planned enrollment
8th of 11
60 · median 102
Started
2021
with 1 other
Phase 1
Only one
of the 14
Registered
11th of 14
by date

Among the 14 studies in Venous Thromboembolism by McMaster University, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2021, is the only one in phase 1, and was the 11th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

2 of the 14 studies in Venous Thromboembolism by McMaster University are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Venous Thromboembolism by McMaster University, or all of them as a file.
02

Study summary

Inflammatory bowel disease (IBD) is a relatively common disease that effects all age groups and carries significant morbidity and mortality. The initial treatment typically involves both short and long term medication, however when this is not enough to adequately control the disease, surgery is often required. The high morbidity and mortality rates are in part due to the increased rates of venous thromboembolism (VTE) such as deep vein thrombosis (DVT) or pulmonary embolism (PE) which have been shown to develop more frequently in IBD patients compared to the general population. Undergoing abdominal surgery has also been shown to independently increase rates of DVT and PE and since the majority of patients with IBD will undergo surgery at least once in their lifetime, the relative increased risk of developing a VTE is very high. The majority of DVT and PE events in the postoperative IBD population will occur after discharge from hospital and therefore carries significant morbidity and mortality risk in a unmonitored setting. Several studies have demonstrated the benefits and safety of twice daily dosing of oral extended VTE prophylaxis agents in orthopedic and cancer postoperative patients following discharge from hospital. There have been no randomized studies which have evaluated the use of extended postoperative VTE prophylaxis in IBD patients. The purpose of this randomized placebo controlled pilot trial will be to evaluate the efficacy and safety of postoperative VTE prophylaxis in IBD patients following abdominal surgery. If this pilot trial demonstrates efficacy in reducing postoperative DVT and PE rates, safety and feasibility, clinicians will be armed with the knowledge to pursue a larger multicenter randomized trial with the intent of reducing overall morbidity and mortality in this high risk population.

03

Conditions studied

  • IBD
  • Venous Thromboembolism
  • Crohn Disease
  • Ulcerative Colitis
  • Pulmonary Embolism
  • Colorectal Disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >18 years old
  • Having documented pathological diagnosis of either Crohn's disease or ulcerative colitis.
  • Open or laparoscopic abdominal gastrointestinal surgery
  • Elective surgery
  • Surgery occurring at Hamilton Health Sciences or St. Joseph's Healthcare Hamilton
  • Negative urine beta-hCG for women of

Exclusion criteria

Exclusion Criteria:

  • to use of postoperative thromboprophylaxis (ie. Previous bleeding on anticoagulation)
  • Allergy to apixaban
  • History of VTE
  • Current active bleeding, including GI bleeding
  • Hepatic disease associated with coagulopathy and clinically relevant bleeding risk
  • Severe renal impairment (eCrCl \<30 ml/min), or undergoing dialysis
  • Lesions or conditions at increased risk of clinically significant bleeding (e.g. recent GI bleeding, recent ischemic or hemorrhagic cerebral infarction, active ulcerative GI disease, recent brain, spinal or ophthalmological surgery, bronchiectasis or history of pulmonary bleeding, thrombocytopenia or functional defects, congenital or acquired coagulation disorder)
  • Receiving any of the following drugs:

    • Strong inhibitors of both CYP 3A4 and P-gp, such as azole-antimycotics (e.g. ketoconazole, itraconazole, voriconazole, or posaconazole), and protease inhibitors (e.g. ritonavir)
    • Strong inducers of both CYP 3A4 and P-gp (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John's Wort)
    • Drug products affecting hemostasis (e.g. NSAIDs, ASA or other antiplatelet agents [e.g. ASA, clopidogrel, prasugrel, ticagrelor], SSRIs, or SNRIs)
    • Any other anticoagulant, including unfractionated heparin, LMWH, heparin derivatives, or oral anticoagulants (e.g. warfarin, dabigatran, rivaroxaban)
  • Currently receiving therapy for any type of (e.g. colorectal, breast, lung)
  • History of colorectal cancer
  • Emergency surgery
  • Patients with an indication for anticoagulation before surgery (atrial fibrillation, etc.)
  • Enrolled in any other clinical trials or prospective studies where similar outcomes are measured
  • Pregnant (i.e. positive pregnancy test and/or self-reported) and/or breastfeeding
  • Women of unwilling/unable to participate in appropriate family planning during the treatment period
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    The placebo group will receive a similarly appearing full supply of a twice daily placebo oral tablet.

    Drug: Placebo Oral Tablet

  • Experimental
    Experimental

    The treatment arm will receive a full supply of twice daily 2.5 milligram (mg) dosing of apixaban beginning on the first day of hospital discharge.

    Drug: Apixaban 2.5 milligram

Interventions

  • DrugApixaban 2.5 milligram

    2.5 milligram daily dosing of Apixaban beginning on the first day of hospital discharge for a total of 30 days

  • DrugPlacebo Oral Tablet

    placebo oral tablet that resembles the experimental drug. To be taken with the same frequency and duration

06

What researchers measure

Primary outcomes

  1. Incidence of post operative venous thromboembolism events (DVT/PE) in in patients with Inflammatory Bowel Disease

    The primary efficacy outcome will be a composite of symptomatic proximal DVTs of the upper and lower extremities, splanchnic VTE, nonfatal PE (segmental or greater artery), and death from PE and death from any cause within 3 months following hospital discharge.

    Time frame: 3 months post operatively

  2. Incidence of bleeding while undergoing treatment with oral anticoagulant or placebo.

    The primary safety outcome will be bleeding reported during treatment, including major bleeding, clinically relevant non-major (CRNM) bleeding, minor bleeding, and the composite of major bleeding and CRNM bleeding.

    Time frame: 3 months post operatively

Secondary outcomes

  1. Incidence of surgical complications related to post operative anticoagulation

    The secondary outcome will include surgical complications related to anticoagulation (intra-abdominal bleeding, surgical site bleeding), and arterial thromboembolic events such as acute ischemic stroke, myocardial infarction, and other VTE (upper extremity and splanchnic veins).

    Time frame: 3 months post operatively

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — This study will not share any individual participant data with other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Dec 2025, 51 months after the start.

Of 16 phase 1 interventional studies under Venous Thromboembolism, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 51 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2019
First posted
May 2, 2019
StartActual
Sep 1, 2021
Primary completionEst.
Dec 31, 2025
CompletionEst.
Feb 1, 2026
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03935451
Responsible party
Sponsor
First posted
May 2, 2019
Start date
Sep 1, 2021
Primary completion
Dec 31, 2025 (estimated)
Completion
Feb 1, 2026 (estimated)
Last update
Jan 5, 2024

Study contacts

Cagla Eskicioglu, MD MSc
Contact
eskicio@mcmaster.ca
(905) 522-1155 ext. 35921
Tyler McKechnie, MD
Contact
tyler.mckechnie@medportal.ca
(905) 522-1155 ext. 35921

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion